secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126323
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q4 revenue $14.7M up 16% YoY; first positive adjusted EBITDA
-------------------------------------------------------------------

- Q4 total revenue $14.7M (+16% YoY); retina $8.9M (+22%), Cyclo G6 $3.8M (+15%).
- Q4 net loss improved to $0.2M ($0.01 EPS) from $0.8M ($0.05 EPS) in Q4 2024.
- FY 2025 revenue $52.7M (+8% YoY); net loss $4.4M ($0.26) vs $8.9M ($0.54) in 2024.
- First positive adjusted EBITDA of $1.1M in FY 2025 (vs -$4.3M in 2024) and Q4 $0.8M.
- FY 2026 guidance: revenue $51M-$53M; positive operating cash flow; OpEx $19M-$19.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000119312526126323/0001193125-26-126323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000119312526126323/irix-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer